jiuwei cui
CD19-targeted CART cells(jiuwei cui)은 CD19 표적 세포·유전자 치료로, Leukemia, B-Cell 영역에서 개발·상용화 중입니다. 작용기전: CAR-T induction, B-cell depletion, therapeutic efficacy, and tissue-level outcomes were assessed in a collagen-induced arthritis (CIA) mouse model. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 39건의 관련 임상이 등록되어 있습니다. 차별점: novel therapy for R/R B-ALL.
CD19
Leukemia, B-Cell
Active
CAR-T outcomes has not been fully elucidated
viral vector-based genetic modification limit its scalability and clinical application
novel therapy for R/R B-ALL
CAR-T induction, B-cell depletion, therapeutic efficacy, and tissue-level outcomes were assessed in a collagen-induced arthritis (CIA) mouse model
T cells exhibited antigen-specific cytotoxicity
CD19 CAR-T infusion induce high
resistance to therapies, and poor survival
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
jiuwei cui
CD19-targeted CART cells(jiuwei cui)은 CD19 표적 세포·유전자 치료로, Leukemia, B-Cell 영역에서 개발·상용화 중입니다. 작용기전: CAR-T induction, B-cell depletion, therapeutic efficacy, and tissue-level outcomes were assessed in a collagen-induced arthritis (CIA) mouse model. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 39건의 관련 임상이 등록되어 있습니다. 차별점: novel therapy for R/R B-ALL.
CD19
Leukemia, B-Cell
Active
CAR-T outcomes has not been fully elucidated
viral vector-based genetic modification limit its scalability and clinical application
novel therapy for R/R B-ALL
CAR-T induction, B-cell depletion, therapeutic efficacy, and tissue-level outcomes were assessed in a collagen-induced arthritis (CIA) mouse model
T cells exhibited antigen-specific cytotoxicity
CD19 CAR-T infusion induce high
resistance to therapies, and poor survival
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.